Christopher Dwight Huston
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christopher Dwight Huston has a total of 204 co-authors. Here are the top co-authors by number of shared publications:
Jose E. Teixeira
University of Vermont Larner College of Medicine
14 shared publicationsPeter Miller
University of Vermont Larner College of Medicine
14 shared publicationsAdam Sateriale
The Francis Crick Institute, London, United Kingdom
10 shared publications- Marvin J. Meyers
Saint Louis University
9 shared publications Erin E. Stebbins
Department of Medicine, University of Vermont Larner College of Medicine
7 shared publicationsJosé E. Teixeira
Department of Medicine, University of Vermont Larner College of Medicine, Room 202 Stafford Hall, 95 Carrigan Drive, Burlington, Vermont, USA
7 shared publications
Latest Publications
- Open Access
- 30 October 2026
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 12 (11) , 3798-3808
A Machine Learning-Enhanced Ligand-Based Workflow Identifies Novel Cryptosporidium parvum Inhibitors
Cryptosporidium parasites are a leading cause of waterborne disease worldwide, causing life-threatening diarrhea and malnutrition in young children and people with HIV. Currently, nitazoxanide is the only FDA-approved treatment, but it is largely ineffective in severely immunocompromised patients, highlighting the need for new therapies. Here, we use a ligand-based virtual screening workflow that integrates Thompson Sampling, a pharmacophore model, and a machine learning classifier to screen a subset of Enamine’s REAL database comprising 51 million virtual compounds. Across two screening campaigns, 20 novel micromolar hits were identified among 69 tested compounds (29%), eight of which exhibited confirmed activity at or below 21 μM. These findings expand the chemical diversity of the original series by introducing new tail and head chemotypes and demonstrate the effectiveness of active learning strategies for improving ligand-based virtual screening performance.
- 30 October 2026
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 12 (11) , 3798-3808
Open AccessA Machine Learning-Enhanced Ligand-Based Workflow Identifies Novel Cryptosporidium parvum Inhibitors
Cryptosporidium parasites are a leading cause of waterborne disease worldwide, causing life-threatening diarrhea and malnutrition in young children and people with HIV. Currently, nitazoxanide is the only FDA-approved treatment, but it is largely ineffective in severely immunocompromised patients, highlighting the need for new therapies. Here, we use a ligand-based virtual screening workflow that integrates Thompson Sampling, a pharmacophore model, and a machine learning classifier to screen a subset of Enamine’s REAL database comprising 51 million virtual compounds. Across two screening campaigns, 20 novel micromolar hits were identified among 69 tested compounds (29%), eight of which exhibited confirmed activity at or below 21 μM. These findings expand the chemical diversity of the original series by introducing new tail and head chemotypes and demonstrate the effectiveness of active learning strategies for improving ligand-based virtual screening performance.
- Open Access
- 27 July 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (15) , 19355-19370
Structure–Activity Relationship Study of Anti- Cryptosporidium Benzoxaboroles Yields Enhanced Potency and Curative Efficacy
Cryptosporidiosis is a major cause of life-threatening diarrhea in children and chronic diarrhea in immunocompromised individuals. Our previous work identified pyrazolo[3,4-d]pyrimidine benzoxaborole (2) as an orally efficacious inhibitor of Cryptosporidium with a downside of relapse after 7 days post drug treatment. Here, we report a structure–activity relationship study around the benzoxaborole ring of compound 2, resulting in rac- 11 with improved in vitro potency (EC50 = 0.025 μM). Remarkably, rac- 11 is noncytotoxic and displayed curative in vivo efficacy in Cryptosporidium-infected immunocompromised NSG mice. Furthermore, resolution of rac-11 into its enantiomers demonstrated that one enantiomer is 2-fold more potent (ent2-11; EC50 = 0.011 μM), whereas the other is 400-fold less potent, highlighting the importance of the methyl group at the C3 position of benzoxaborole. The ent2-11 also had reduced adverse binding to hPDE5 compared to 2. Collectively, these findings advance new and effective candidates for the treatment of cryptosporidiosis.
- 27 July 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (15) , 19355-19370
Open AccessStructure–Activity Relationship Study of Anti- Cryptosporidium Benzoxaboroles Yields Enhanced Potency and Curative Efficacy
Cryptosporidiosis is a major cause of life-threatening diarrhea in children and chronic diarrhea in immunocompromised individuals. Our previous work identified pyrazolo[3,4-d]pyrimidine benzoxaborole (2) as an orally efficacious inhibitor of Cryptosporidium with a downside of relapse after 7 days post drug treatment. Here, we report a structure–activity relationship study around the benzoxaborole ring of compound 2, resulting in rac- 11 with improved in vitro potency (EC50 = 0.025 μM). Remarkably, rac- 11 is noncytotoxic and displayed curative in vivo efficacy in Cryptosporidium-infected immunocompromised NSG mice. Furthermore, resolution of rac-11 into its enantiomers demonstrated that one enantiomer is 2-fold more potent (ent2-11; EC50 = 0.011 μM), whereas the other is 400-fold less potent, highlighting the importance of the methyl group at the C3 position of benzoxaborole. The ent2-11 also had reduced adverse binding to hPDE5 compared to 2. Collectively, these findings advance new and effective candidates for the treatment of cryptosporidiosis.
- Open Access
- 18 February 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Development of a Current Good Manufacturing Practice–Compliant Process for Producing Cryptosporidium parvum Oocysts for Clinical Use
Background: Cryptosporidiosis is a leading cause of severe diarrhea and mortality in young children, with no vaccine or effective treatment. A Cryptosporidium controlled human infection model (CHIM) in healthy adults provides an opportunity to evaluate the safety and efficacy of novel chemical entities prior to testing in young pediatric patients. However, CHIM development has been hindered by the lack of current Good Manufacturing Practice (cGMP)–compliant Cryptosporidium parvum oocysts, which are required for filing an Investigational New Drug (IND) application with the US Food and Drug Administration. Methods: To overcome this barrier, we developed a cGMP-compliant process for producing C. parvum oocysts. The approach involved sourcing well-characterized oocysts purified from neonatal calves under controlled non-GMP conditions, followed by cGMP processing that included peracetic acid–based surface sanitization, comprehensive microbial testing, and release as a nonsterile oral product for human use. Results: Peracetic acid (0.5% for 20 minutes) treated C. parvum oocysts demonstrated acceptable microbial safety and preserved viability. Viability was assessed through oocyst excystation, HCT-8 cell infection, and mouse infectivity studies. The cGMP-produced C. parvum oocysts with stringent batch release test criteria for quantity, purity, identity, potency, and bioburden was released as ABO809 for clinical use under an IND. ABO809 was successfully used in human challenge studies, producing reliable infection and characteristic clinical symptoms in healthy adult volunteers. Conclusions: We describe a robust cGMP-compliant and qualification process for C. parvum oocysts that enables CHIM studies in healthy adults, thereby opening avenues to evaluate efficacy of novel therapeutics and vaccines to treat cryptosporidiosis.
- 18 February 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Open AccessDevelopment of a Current Good Manufacturing Practice–Compliant Process for Producing Cryptosporidium parvum Oocysts for Clinical Use
Background: Cryptosporidiosis is a leading cause of severe diarrhea and mortality in young children, with no vaccine or effective treatment. A Cryptosporidium controlled human infection model (CHIM) in healthy adults provides an opportunity to evaluate the safety and efficacy of novel chemical entities prior to testing in young pediatric patients. However, CHIM development has been hindered by the lack of current Good Manufacturing Practice (cGMP)–compliant Cryptosporidium parvum oocysts, which are required for filing an Investigational New Drug (IND) application with the US Food and Drug Administration. Methods: To overcome this barrier, we developed a cGMP-compliant process for producing C. parvum oocysts. The approach involved sourcing well-characterized oocysts purified from neonatal calves under controlled non-GMP conditions, followed by cGMP processing that included peracetic acid–based surface sanitization, comprehensive microbial testing, and release as a nonsterile oral product for human use. Results: Peracetic acid (0.5% for 20 minutes) treated C. parvum oocysts demonstrated acceptable microbial safety and preserved viability. Viability was assessed through oocyst excystation, HCT-8 cell infection, and mouse infectivity studies. The cGMP-produced C. parvum oocysts with stringent batch release test criteria for quantity, purity, identity, potency, and bioburden was released as ABO809 for clinical use under an IND. ABO809 was successfully used in human challenge studies, producing reliable infection and characteristic clinical symptoms in healthy adult volunteers. Conclusions: We describe a robust cGMP-compliant and qualification process for C. parvum oocysts that enables CHIM studies in healthy adults, thereby opening avenues to evaluate efficacy of novel therapeutics and vaccines to treat cryptosporidiosis.
- Open Access
- 25 June 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (8) , e0050225
Organoid-based in vitro system and reporter for the study of Cryptosporidium parvum sexual reproduction
Many advances have been made recently in our understanding of Cryptosporidium ’s asexual cycle and sexual differentiation. However, the process of fertilization, which is required for transmission of infectious oocysts, is not well understood. Typical cancer cell-based culture only allows robust exploration of asexual cycle and sexual differentiation of Cryptosporidium . To facilitate exploration of sexual reproduction in Cryptosporidium parvum, we developed an organoid-based culture system that supports Cryptosporidium’s full life cycle and a novel fertilization reporter. Organoid-derived monolayers (ODMs) supported fertilization and oocyst production and maintained the infection for up to 3 weeks. ODM-derived oocysts were infectious in vivo . Fertilization was confirmed by successfully mating two strains of C. parvum and with a novel fertilization switch reporter. The fertilization switch reporter utilizes a DiCre system in which cre fragments are expressed under the control of sexual stage promoters, resulting in a rapamycin-inducible switch in fluorescent protein expression from mCherry to mNeonGreen after fertilization that is spatially and temporally controlled. This results in mCherry-positive parasites in the first generation and offspring that express mNeonGreen. In vivo validation of the fertilization switch reporter demonstrated the precision and efficiency of the fertilization switch reporter and confirmed excision of the mCherry gene sequence only after rapamycin treatment. The start of a second generation of parasites was also shown in the ODMs and rarely in HCT8s. Use of this reporter in ODMs can help investigate the Cryptosporidium life cycle post-sexual differentiation in a physiologically relevant in vitro system. IMPORTANCE: Organoid-derived monolayers enable the study of previously inaccessible aspects of Cryptosporidium ’s biology. This system overcomes the disadvantages of previous organoid-based methods for Cryptosporidium culture. It is faster and simpler than previously described systems, uses defined differentiation media to increase reproducibility, enables real-time observation, supports parasite fertilization and oocyst production, and provides a physiologically relevant tissue culture system to facilitate cell biology studies. The organoid-derived monolayer system could facilitate the study of host-pathogen interactions, Cryptosporidium -host specificity, or innate or cellular immune responses to Cryptosporidium infection stimulated in the intestinal epithelium. The fertilization switch reporter could be used to test factors or drugs that may have potential to interfere with Cryptosporidium’s sexual reproduction. Organoid-based cell cultures in combination with the fertilization switch reporter could increase our understanding of sexual reproduction in Cryptosporidium, leading to vital information for the development of sexual reproduction inhibitors or vaccines that could shorten disease duration and prevent transmission.
- 25 June 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (8) , e0050225
Open AccessOrganoid-based in vitro system and reporter for the study of Cryptosporidium parvum sexual reproduction
Many advances have been made recently in our understanding of Cryptosporidium ’s asexual cycle and sexual differentiation. However, the process of fertilization, which is required for transmission of infectious oocysts, is not well understood. Typical cancer cell-based culture only allows robust exploration of asexual cycle and sexual differentiation of Cryptosporidium . To facilitate exploration of sexual reproduction in Cryptosporidium parvum, we developed an organoid-based culture system that supports Cryptosporidium’s full life cycle and a novel fertilization reporter. Organoid-derived monolayers (ODMs) supported fertilization and oocyst production and maintained the infection for up to 3 weeks. ODM-derived oocysts were infectious in vivo . Fertilization was confirmed by successfully mating two strains of C. parvum and with a novel fertilization switch reporter. The fertilization switch reporter utilizes a DiCre system in which cre fragments are expressed under the control of sexual stage promoters, resulting in a rapamycin-inducible switch in fluorescent protein expression from mCherry to mNeonGreen after fertilization that is spatially and temporally controlled. This results in mCherry-positive parasites in the first generation and offspring that express mNeonGreen. In vivo validation of the fertilization switch reporter demonstrated the precision and efficiency of the fertilization switch reporter and confirmed excision of the mCherry gene sequence only after rapamycin treatment. The start of a second generation of parasites was also shown in the ODMs and rarely in HCT8s. Use of this reporter in ODMs can help investigate the Cryptosporidium life cycle post-sexual differentiation in a physiologically relevant in vitro system. IMPORTANCE: Organoid-derived monolayers enable the study of previously inaccessible aspects of Cryptosporidium ’s biology. This system overcomes the disadvantages of previous organoid-based methods for Cryptosporidium culture. It is faster and simpler than previously described systems, uses defined differentiation media to increase reproducibility, enables real-time observation, supports parasite fertilization and oocyst production, and provides a physiologically relevant tissue culture system to facilitate cell biology studies. The organoid-derived monolayer system could facilitate the study of host-pathogen interactions, Cryptosporidium -host specificity, or innate or cellular immune responses to Cryptosporidium infection stimulated in the intestinal epithelium. The fertilization switch reporter could be used to test factors or drugs that may have potential to interfere with Cryptosporidium’s sexual reproduction. Organoid-based cell cultures in combination with the fertilization switch reporter could increase our understanding of sexual reproduction in Cryptosporidium, leading to vital information for the development of sexual reproduction inhibitors or vaccines that could shorten disease duration and prevent transmission.
- Open Access
- 23 October 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (770) , eadm8631
Cryptosporidium lysyl-tRNA synthetase inhibitors define the interplay between solubility and permeability required to achieve efficacy
Cryptosporidiosis is a diarrheal disease caused by infection with Cryptosporidium spp. parasites and is a leading cause of death in malnourished children worldwide. The only approved treatment, nitazoxanide, has limited efficacy in this at-risk patient population. Additional safe therapeutics are urgently required to tackle this unmet medical need. However, the development of anti-cryptosporidial drugs is hindered by a lack of understanding of the optimal compound properties required to treat this gastrointestinal infection. To address this knowledge gap, a diverse set of potent lysyl-tRNA synthetase inhibitors was profiled to identify optimal physicochemical and pharmacokinetic properties required for efficacy in a chronic mouse model of infection. The results from this comprehensive study illustrated the importance of balancing solubility and permeability to achieve efficacy in vivo. Our results establish in vitro criteria for solubility and permeability that are predictive of compound efficacy in vivo to guide the optimization of anti-cryptosporidial drugs. Two compounds from chemically distinct series (DDD489 and DDD508) were identified as demonstrating superior efficacy and prioritized for further evaluation. Both compounds achieved marked parasite reduction in immunocompromised mouse models and a disease-relevant calf model of infection. On the basis of these promising data, these compounds have been selected for progression to preclinical safety studies, expanding the portfolio of potential treatments for this neglected infectious disease.
- 23 October 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (770) , eadm8631
Open AccessCryptosporidium lysyl-tRNA synthetase inhibitors define the interplay between solubility and permeability required to achieve efficacy
Cryptosporidiosis is a diarrheal disease caused by infection with Cryptosporidium spp. parasites and is a leading cause of death in malnourished children worldwide. The only approved treatment, nitazoxanide, has limited efficacy in this at-risk patient population. Additional safe therapeutics are urgently required to tackle this unmet medical need. However, the development of anti-cryptosporidial drugs is hindered by a lack of understanding of the optimal compound properties required to treat this gastrointestinal infection. To address this knowledge gap, a diverse set of potent lysyl-tRNA synthetase inhibitors was profiled to identify optimal physicochemical and pharmacokinetic properties required for efficacy in a chronic mouse model of infection. The results from this comprehensive study illustrated the importance of balancing solubility and permeability to achieve efficacy in vivo. Our results establish in vitro criteria for solubility and permeability that are predictive of compound efficacy in vivo to guide the optimization of anti-cryptosporidial drugs. Two compounds from chemically distinct series (DDD489 and DDD508) were identified as demonstrating superior efficacy and prioritized for further evaluation. Both compounds achieved marked parasite reduction in immunocompromised mouse models and a disease-relevant calf model of infection. On the basis of these promising data, these compounds have been selected for progression to preclinical safety studies, expanding the portfolio of potential treatments for this neglected infectious disease.
- Open Access
- 27 September 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Identification of potent and orally efficacious phosphodiesterase inhibitors in Cryptosporidium parvum-infected immunocompromised male mice
Cryptosporidium parvum and C. hominis are parasites that cause life-threatening diarrhea in children and immunocompromised people. There is only one approved treatment that is modestly effective for children and ineffective for AIDS patients. Here, screening 278 compounds from the Merck KGaA, Darmstadt, Germany collection and accelerated follow-up enabled by prior investigation of the compounds identifies a series of pyrazolopyrimidine human phosphodiesterase (PDE)-V (hPDE-V) inhibitors with potent anticryptosporidial activity and efficacy following oral administration in C. parvum-infected male mice. The lead compounds affect parasite host cell egress, inhibit both C. parvum and C. hominis, work rapidly, and have minimal off-target effects in a safety screening panel. Interestingly, the hPDE-V inhibitors sildenafil and the 4-aminoquinoline compound 7a do not affect Cryptosporidium. C. parvum expresses one PDE (CpPDE1) continuously during asexual growth, the inhibited life stage. According to homology modeling and docking, the lead compounds interact with CpPDE1. Bulkier amino acids (Val900 and His884) in the CpPDE1 active site replace alanines in hPDE-V and block sildenafil binding. Supporting this, sildenafil kills a CRISPR-engineered Cryptosporidium CpPDE1 V900A mutant. The CpPDE1 mutation also alters parasite susceptibility to pyrazolopyrimidines. CpPDE1 is therefore a validated pyrazolopyrimidine molecular target to exploit for target-based optimization for improved anticryptosporidial development.
- 27 September 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Open AccessIdentification of potent and orally efficacious phosphodiesterase inhibitors in Cryptosporidium parvum-infected immunocompromised male mice
Cryptosporidium parvum and C. hominis are parasites that cause life-threatening diarrhea in children and immunocompromised people. There is only one approved treatment that is modestly effective for children and ineffective for AIDS patients. Here, screening 278 compounds from the Merck KGaA, Darmstadt, Germany collection and accelerated follow-up enabled by prior investigation of the compounds identifies a series of pyrazolopyrimidine human phosphodiesterase (PDE)-V (hPDE-V) inhibitors with potent anticryptosporidial activity and efficacy following oral administration in C. parvum-infected male mice. The lead compounds affect parasite host cell egress, inhibit both C. parvum and C. hominis, work rapidly, and have minimal off-target effects in a safety screening panel. Interestingly, the hPDE-V inhibitors sildenafil and the 4-aminoquinoline compound 7a do not affect Cryptosporidium. C. parvum expresses one PDE (CpPDE1) continuously during asexual growth, the inhibited life stage. According to homology modeling and docking, the lead compounds interact with CpPDE1. Bulkier amino acids (Val900 and His884) in the CpPDE1 active site replace alanines in hPDE-V and block sildenafil binding. Supporting this, sildenafil kills a CRISPR-engineered Cryptosporidium CpPDE1 V900A mutant. The CpPDE1 mutation also alters parasite susceptibility to pyrazolopyrimidines. CpPDE1 is therefore a validated pyrazolopyrimidine molecular target to exploit for target-based optimization for improved anticryptosporidial development.
- Open Access
- 26 April 2024
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 20 (4) , e1011906
Cryptosporidium life cycle small molecule probing implicates translational repression and an Apetala 2 transcription factor in macrogamont differentiation
The apicomplexan parasite Cryptosporidium is a leading cause of childhood diarrhea in developing countries. Current treatment options are inadequate and multiple preclinical compounds are being actively pursued as potential drugs for cryptosporidiosis. Unlike most apicomplexans, Cryptosporidium spp. sequentially replicate asexually and then sexually within a single host to complete their lifecycles. Anti-cryptosporidial compounds are generally identified or tested through in vitro phenotypic assays that only assess the asexual stages. Therefore, compounds that specifically target the sexual stages remain unexplored. In this study, we leveraged the ReFRAME drug repurposing library against a newly devised multi-readout imaging assay to identify small-molecule compounds that modulate macrogamont differentiation and maturation. RNA-seq studies confirmed selective modulation of macrogamont differentiation for 10 identified compounds (9 inhibitors and 1 accelerator). The collective transcriptomic profiles of these compounds indicates that translational repression accompanies Cryptosporidium sexual differentiation, which we validated experimentally. Additionally, cross comparison of the RNA-seq data with promoter sequence analysis for stage-specific genes converged on a key role for an Apetala 2 (AP2) transcription factor (cgd2_3490) in differentiation into macrogamonts. Finally, drug annotation for the ReFRAME hits indicates that an elevated supply of energy equivalence in the host cell is critical for macrogamont formation.
- 26 April 2024
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 20 (4) , e1011906
Open AccessCryptosporidium life cycle small molecule probing implicates translational repression and an Apetala 2 transcription factor in macrogamont differentiation
The apicomplexan parasite Cryptosporidium is a leading cause of childhood diarrhea in developing countries. Current treatment options are inadequate and multiple preclinical compounds are being actively pursued as potential drugs for cryptosporidiosis. Unlike most apicomplexans, Cryptosporidium spp. sequentially replicate asexually and then sexually within a single host to complete their lifecycles. Anti-cryptosporidial compounds are generally identified or tested through in vitro phenotypic assays that only assess the asexual stages. Therefore, compounds that specifically target the sexual stages remain unexplored. In this study, we leveraged the ReFRAME drug repurposing library against a newly devised multi-readout imaging assay to identify small-molecule compounds that modulate macrogamont differentiation and maturation. RNA-seq studies confirmed selective modulation of macrogamont differentiation for 10 identified compounds (9 inhibitors and 1 accelerator). The collective transcriptomic profiles of these compounds indicates that translational repression accompanies Cryptosporidium sexual differentiation, which we validated experimentally. Additionally, cross comparison of the RNA-seq data with promoter sequence analysis for stage-specific genes converged on a key role for an Apetala 2 (AP2) transcription factor (cgd2_3490) in differentiation into macrogamonts. Finally, drug annotation for the ReFRAME hits indicates that an elevated supply of energy equivalence in the host cell is critical for macrogamont formation.
- Open Access
Cryptosporidium Life Cycle Small Molecule Probing Implicates Translational Repression And An Apetala 2 Transcription Factor In Sexual Differentiation
The apicomplexan parasite Cryptosporidium is a leading cause of childhood diarrhea in developing countries. Current treatment options are inadequate and multiple preclinical compounds are being actively pursued as potential drugs for cryptosporidiosis. Unlike most apicomplexans, Cryptosporidium spp. sequentially replicate asexually and then sexually within a single host to complete their lifecycles. Anti-cryptosporidial compounds are generally identified or tested through in vitro phenotypic assays that only assess the asexual stages. Therefore, compounds that specifically target the sexual stages remain unexplored. In this study, we leveraged the ReFRAME drug repurposing library against a newly devised multi-readout imaging assay to identify small-molecule compounds that modulate sexual differentiation and maturation. mRNA-seq studies confirmed selective modulation of sexual differentiation for 10 hit compounds (9 inhibitors and 1 accelerator). The collective transcriptomic profiles of these compounds indicates that translational repression accompanies Cryptosporidium sexual differentiation, which we validated experimentally. Additionally, cross comparison of the RNA-seq data with promoter sequence analysis for stage-specific genes converged on a key role for an Apetala 2 (AP2) transcription factor (cgd2_3490) in sexual differentiation. Finally, drug annotation for the ReFRAME hits indicates that an elevated supply of energy equivalence in the host cell is critical for gamont formation.
Open AccessCryptosporidium Life Cycle Small Molecule Probing Implicates Translational Repression And An Apetala 2 Transcription Factor In Sexual Differentiation
The apicomplexan parasite Cryptosporidium is a leading cause of childhood diarrhea in developing countries. Current treatment options are inadequate and multiple preclinical compounds are being actively pursued as potential drugs for cryptosporidiosis. Unlike most apicomplexans, Cryptosporidium spp. sequentially replicate asexually and then sexually within a single host to complete their lifecycles. Anti-cryptosporidial compounds are generally identified or tested through in vitro phenotypic assays that only assess the asexual stages. Therefore, compounds that specifically target the sexual stages remain unexplored. In this study, we leveraged the ReFRAME drug repurposing library against a newly devised multi-readout imaging assay to identify small-molecule compounds that modulate sexual differentiation and maturation. mRNA-seq studies confirmed selective modulation of sexual differentiation for 10 hit compounds (9 inhibitors and 1 accelerator). The collective transcriptomic profiles of these compounds indicates that translational repression accompanies Cryptosporidium sexual differentiation, which we validated experimentally. Additionally, cross comparison of the RNA-seq data with promoter sequence analysis for stage-specific genes converged on a key role for an Apetala 2 (AP2) transcription factor (cgd2_3490) in sexual differentiation. Finally, drug annotation for the ReFRAME hits indicates that an elevated supply of energy equivalence in the host cell is critical for gamont formation.
- Open Access
Organoid-based in vitro system and reporter for the study of Cryptosporidium parvum sexual reproduction
Many advances have been made recently in our understanding of Cryptosporidium ’s asexual cycle and sexual differentiation. However, the process of fertilization, which is required for transmission of infectious oocysts, is not well understood. Typical cancer cell-based culture only allows robust exploration of asexual cycle and sexual differentiation of Cryptosporidium . To facilitate exploration of sexual reproduction in C. parvum we developed an organoid-based culture system that supports Cryptosporidium’s full life cycle and a novel fertilization reporter. Organoid derived monolayers (ODMs) supported fertilization and oocyst production and maintained the infection for up to 3 weeks. ODM derived oocysts were infectious in vivo . Fertilization was confirmed by successfully mating two strains of C. parvum and with a novel fertilization switch reporter. The fertilization switch reporter utilizes a DiCre system in which cre fragments are expressed under the control of sexual stage promoters resulting in a rapamycin-inducible switch in fluorescent protein expression from mCherry to mNeonGreen after fertilization that is spatially and temporally controlled. This results in mCherry positive parasites in the first generation and offspring that express mNeonGreen. In vivo validation of the fertilization switch reporter demonstrated the precision and efficiency of the fertilization switch reporter and confirmed excision of the mCherry gene sequence only after rapamycin treatment. The start of a second generation of parasites was also shown in the ODMs and rarely in HCT8s. Use of this reporter in ODMs can help investigate the Cryptosporidium lifecycle post sexual differentiation in a physiologically relevant in vitro system. Importance: Organoid derived monolayers provide an opportunity to elucidate previously inaccessible aspects of Cryptosporidium ’s biology. This system overcomes the disadvantages of previous organoid-based methods for Cryptosporidium culture. It is faster and simpler than previously described systems, uses defined media to increase reproducibility and consistency, enables real-time observation, supports parasite fertilization and oocyst production, and provides a physiologically relevant tissue culture system to facilitate studies of Cryptosporidium cell biology. The ODM system could facilitate the study of host-pathogen interactions, Cryptosporidium -host specificity, or innate or cellular immune responses to Cryptosporidium infection stimulated in the intestinal epithelium. The fertilization switch reporter could be used to test factors or drugs that may have potential to interfere with Cryptosporidium’s sexual reproduction. Organoid-based cell cultures in combination with the fertilization switch reporter could increase our understanding of sexual reproduction in Cryptosporidium, leading to vital information for the development of sexual reproduction inhibitors or vaccines that could shorten disease duration and prevent transmission.
Open AccessOrganoid-based in vitro system and reporter for the study of Cryptosporidium parvum sexual reproduction
Many advances have been made recently in our understanding of Cryptosporidium ’s asexual cycle and sexual differentiation. However, the process of fertilization, which is required for transmission of infectious oocysts, is not well understood. Typical cancer cell-based culture only allows robust exploration of asexual cycle and sexual differentiation of Cryptosporidium . To facilitate exploration of sexual reproduction in C. parvum we developed an organoid-based culture system that supports Cryptosporidium’s full life cycle and a novel fertilization reporter. Organoid derived monolayers (ODMs) supported fertilization and oocyst production and maintained the infection for up to 3 weeks. ODM derived oocysts were infectious in vivo . Fertilization was confirmed by successfully mating two strains of C. parvum and with a novel fertilization switch reporter. The fertilization switch reporter utilizes a DiCre system in which cre fragments are expressed under the control of sexual stage promoters resulting in a rapamycin-inducible switch in fluorescent protein expression from mCherry to mNeonGreen after fertilization that is spatially and temporally controlled. This results in mCherry positive parasites in the first generation and offspring that express mNeonGreen. In vivo validation of the fertilization switch reporter demonstrated the precision and efficiency of the fertilization switch reporter and confirmed excision of the mCherry gene sequence only after rapamycin treatment. The start of a second generation of parasites was also shown in the ODMs and rarely in HCT8s. Use of this reporter in ODMs can help investigate the Cryptosporidium lifecycle post sexual differentiation in a physiologically relevant in vitro system. Importance: Organoid derived monolayers provide an opportunity to elucidate previously inaccessible aspects of Cryptosporidium ’s biology. This system overcomes the disadvantages of previous organoid-based methods for Cryptosporidium culture. It is faster and simpler than previously described systems, uses defined media to increase reproducibility and consistency, enables real-time observation, supports parasite fertilization and oocyst production, and provides a physiologically relevant tissue culture system to facilitate studies of Cryptosporidium cell biology. The ODM system could facilitate the study of host-pathogen interactions, Cryptosporidium -host specificity, or innate or cellular immune responses to Cryptosporidium infection stimulated in the intestinal epithelium. The fertilization switch reporter could be used to test factors or drugs that may have potential to interfere with Cryptosporidium’s sexual reproduction. Organoid-based cell cultures in combination with the fertilization switch reporter could increase our understanding of sexual reproduction in Cryptosporidium, leading to vital information for the development of sexual reproduction inhibitors or vaccines that could shorten disease duration and prevent transmission.
- Open Access
Identification of potent and orally efficacious phosphodiesterase inhibitors in s Cryptosporidium parvum- infected immunocompromised mice
Cryptosporidium species, mostly C. parvum and C. hominis in humans, are intestinal apicomplexan parasites that cause life-threatening diarrhea in young children and people with cell-mediated immune defects, such as due to AIDS. There is only one approved treatment for cryptosporidiosis, but it is ineffective for immunocompromised people and only modestly effective for children. In this study, screening 278 compounds from the Merck KGaA, Darmstadt, Germany collection and accelerated follow-up work enabled by prior investigation of the compounds resulted in identification of a series of pyrazolopyrimidine human phosphodiesterase (PDE)-V inhibitors with potent anticryptosporidial activity and efficacy following oral administration in C. parvum -infected immunocompromised mice. The novel PDE inhibitor leads ( compounds PDEi2 and PDEi5 ) affect parasite egress from infected host cells. They have comparable activity against C. parvum and C. hominis , rapidly eliminate C. parvum in tissue culture, and have minimal off-target effects in a panel of safety screening assays. In comparison, the potent human PDE-V inhibitors sildenafil and the 4-aminoquinoline compound 7a have no useful activity against C. parvum. Based on homology modeling and in silico compound docking, PDEi5 interacts directly with an active-site metal ion and docks well to two C. parvum PDEs. In contrast, larger amino acid side groups (Val900/Tyr11128 and His884/Asn1112) in both C. parvum PDEs replace alanine in human PDE-V and block sildenafil binding, explaining its lack of efficacy. These results identify a promising new drug target and lead series for anticryptosporidial drug development and validates a route to target-based optimization.
Open AccessIdentification of potent and orally efficacious phosphodiesterase inhibitors in s Cryptosporidium parvum- infected immunocompromised mice
Cryptosporidium species, mostly C. parvum and C. hominis in humans, are intestinal apicomplexan parasites that cause life-threatening diarrhea in young children and people with cell-mediated immune defects, such as due to AIDS. There is only one approved treatment for cryptosporidiosis, but it is ineffective for immunocompromised people and only modestly effective for children. In this study, screening 278 compounds from the Merck KGaA, Darmstadt, Germany collection and accelerated follow-up work enabled by prior investigation of the compounds resulted in identification of a series of pyrazolopyrimidine human phosphodiesterase (PDE)-V inhibitors with potent anticryptosporidial activity and efficacy following oral administration in C. parvum -infected immunocompromised mice. The novel PDE inhibitor leads ( compounds PDEi2 and PDEi5 ) affect parasite egress from infected host cells. They have comparable activity against C. parvum and C. hominis , rapidly eliminate C. parvum in tissue culture, and have minimal off-target effects in a panel of safety screening assays. In comparison, the potent human PDE-V inhibitors sildenafil and the 4-aminoquinoline compound 7a have no useful activity against C. parvum. Based on homology modeling and in silico compound docking, PDEi5 interacts directly with an active-site metal ion and docks well to two C. parvum PDEs. In contrast, larger amino acid side groups (Val900/Tyr11128 and His884/Asn1112) in both C. parvum PDEs replace alanine in human PDE-V and block sildenafil binding, explaining its lack of efficacy. These results identify a promising new drug target and lead series for anticryptosporidial drug development and validates a route to target-based optimization.